Abstract
This review focuses on advances in chemistry and pharmacology of synthetic triterpenoid dimers, obtained from natural compounds. Synthetic triterpenoid dimers are divided into specific subgroups based on the structure of main triterpenoid monomeric skeleton. Synthetic triterpenoid derivatives of dimeric structure can be obtained through the covalent linkage of the C-3 hydroxyl or another group, via the C-2 atom or the C-17 carboxyl group (mainly anhydrides, amides or esters). Some triterpenes can undergo chemical transformations leading to the formation of cyclic dimers or other types of dimers. Most of the obtained triterpenoid dimers have been subjected to pharmacological tests evaluating their biological activity, mainly antiviral (HIV-1 RT, HCVpp, VSVpp, HIV-RT-C8166-CCR5), cytotoxic (against e.g. 388, MCF-7, SF-268, NCIH460, KM20L2, DU-145, Hep-G2, A549, BGC-823, PC-3), anti-inflammatory (iNOS, RAW 264.7) and antidiabetic (RMGPa inhibition). The authors also reported the ability of some of the obtained cyclic triterpenoid dimers to recognize anions and to form self-assembled structures.
Keywords: Triterpenes, triterpenoid dimers, dimerization, synthetic dimers, derivatives of triterpenes, pharmacological activity of triterpenes.
Current Medicinal Chemistry
Title:Advances in Chemistry and Pharmacology of Triterpenoid Synthetic Dimers
Volume: 24 Issue: 20
Author(s): Barbara Bednarczyk-Cwynar*Andrzej Günther
Affiliation:
- Department of Organic Chemistry, Faculty of Pharmacy, Poznan University of Medical Sciences, Grunwaldzka 6, 60 – 780 Poznan,Poland
Keywords: Triterpenes, triterpenoid dimers, dimerization, synthetic dimers, derivatives of triterpenes, pharmacological activity of triterpenes.
Abstract: This review focuses on advances in chemistry and pharmacology of synthetic triterpenoid dimers, obtained from natural compounds. Synthetic triterpenoid dimers are divided into specific subgroups based on the structure of main triterpenoid monomeric skeleton. Synthetic triterpenoid derivatives of dimeric structure can be obtained through the covalent linkage of the C-3 hydroxyl or another group, via the C-2 atom or the C-17 carboxyl group (mainly anhydrides, amides or esters). Some triterpenes can undergo chemical transformations leading to the formation of cyclic dimers or other types of dimers. Most of the obtained triterpenoid dimers have been subjected to pharmacological tests evaluating their biological activity, mainly antiviral (HIV-1 RT, HCVpp, VSVpp, HIV-RT-C8166-CCR5), cytotoxic (against e.g. 388, MCF-7, SF-268, NCIH460, KM20L2, DU-145, Hep-G2, A549, BGC-823, PC-3), anti-inflammatory (iNOS, RAW 264.7) and antidiabetic (RMGPa inhibition). The authors also reported the ability of some of the obtained cyclic triterpenoid dimers to recognize anions and to form self-assembled structures.
Export Options
About this article
Cite this article as:
Bednarczyk-Cwynar Barbara*, Günther Andrzej, Advances in Chemistry and Pharmacology of Triterpenoid Synthetic Dimers, Current Medicinal Chemistry 2017; 24 (20) . https://dx.doi.org/10.2174/0929867324666170202151625
DOI https://dx.doi.org/10.2174/0929867324666170202151625 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Yin and Yang of the Ghrelin Gene Products
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Targeting Interleukin-21 in Immune-Mediated Pathologies
Current Drug Targets Neuropilin-1 (NRP-1) and Magnetic Nanoparticles, a Potential Combination for Diagnosis and Therapy of Gliomas
Current Pharmaceutical Design Recurrence in Bladder Cancer: A Molecular Dead End?
Current Genomics Role of Genetic and Epigenetic Factors in Oral Squamous Cell Carcinoma - A Structured Review
Recent Patents on Biomarkers The Chemistry and Pharmacology of Genistein
The Natural Products Journal Natural Anti-Cancer Agents: Implications in Gemcitabine-Resistant Pancreatic Cancer Treatment
Mini-Reviews in Medicinal Chemistry Plants vs. Cancer: A Review on Natural Phytochemicals in Preventing and Treating Cancers and Their Druggability
Anti-Cancer Agents in Medicinal Chemistry Insulin Delivery Systems for Controlling Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Applications of Mesoporous Materials as Excipients for Innovative Drug Delivery and Formulation
Current Pharmaceutical Design Improvement of Nonviral Gene Therapy by Epstein-Barr Virus (EBV)-based Plasmid Vectors
Current Gene Therapy Hypogonadotrophic Hypogonadism in Type 2 Diabetes, Obesity and the Metabolic Syndrome
Current Molecular Medicine TRP Channels as A Newly Emerging Non-Voltage-Gated Ca2+ Entry Channel Superfamily
Current Pharmaceutical Design New Platinum and Ruthenium Complexes - the Latest Class of Potential Chemotherapeutic Drugs - a Review of Recent Developments in the Field
Mini-Reviews in Medicinal Chemistry CXCR4 and Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry A Comparative Study of Glucose and Fructose in the Development of Sarcoma 180 in Mice
Letters in Organic Chemistry Type 1 11 β-hydroxysteroid Dehydrogenase as Universal Drug Target in Metabolic Diseases?
Endocrine, Metabolic & Immune Disorders - Drug Targets Metal Oxide Nanomaterials in Nanomedicine: Applications in Photodynamic Therapy and Potential Toxicity
Current Topics in Medicinal Chemistry The Non-Canonical IκB Kinases IKKε and TBK1 as Potential Targets for the Development of Novel Therapeutic Drugs
Current Molecular Medicine Evidences and Opinions for Adjuvant Therapy in Pancreatic Cancer
Current Drug Targets